J Korean Diabetes.  2023 Dec;24(4):199-203. 10.4093/jkd.2023.24.4.199.

Characterization and Subgrouping of Type 2 Diabetes

• Cho Y

• KMID: 2550159
• DOI: http://doi.org/10.4093/jkd.2023.24.4.199

Abstract

Among patients with type 2 diabetes, there exists considerable clinical heterogeneity, with variable mechanisms leading to disease onset. These differences may impact treatment responses and the course of the disease. Subgrouping diabetes aims to foster precision diagnostics to allow precision treatment. It is designed to better understand the diversity/heterogeneity within type 2 diabetes and to provide tailored therapies for specific subgroups of patients. There are two subgrouping approaches. The first is a “simple” method of categorizing patients based on specific clinical factors, which is practical but has not consistently improved clinical outcomes. The “complex” approach utilizes machine learning and considers various clinical and/or genomic data, demonstrating reproducible subgroups and associations with clinical outcomes. Nonetheless, whether these efforts translate into significantly superior outcomes compared to current standard treatments remains to be conclusively established and should be addressed in further research.

Keyword

Classification; Diabetes mellitus, type 2; Precision medicine

Reference

1.Choi JH., Lee KA., Moon JH., Chon S., Kim DJ., Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023. 47:575–94.

2.Arner P., Pollare T., Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991. 34:483–7.

3.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S140–57.

4.Castaneda C., Nalley K., Mannion C., Bhattacharyya P., Blake P., Pecora A, et al. Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. J Clin Bioinforma. 2015. 5:4.

5.Chung WK., Erion K., Florez JC., Hattersley AT., Hivert MF., Lee CG, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020. 43:1617–35.

6.Misra S., Wagner R., Ozkan B., Schön M., Sevilla-Gonzalez M., Prystupa K, et al. Precision subclassification of type 2 diabetes: a systematic review. Commun Med (Lond). 2023. 3:138.

7.Cho Y., Park HS., Huh BW., Seo SH., Seo DH., Ahn SH, et al. Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitus. Diabetes Metab. 2022. 48:101389.

8.Mohammedi K., Chalmers J., Herrington W., Li Q., Mancia G., Marre M, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018. 8:7.

9.Ahlqvist E., Storm P., Käräjämäki A., Martinell M., Dorkhan M., Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018. 6:361–9.

10.Zou X., Zhou X., Zhu Z., Ji L. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol. 2019. 7:9–11.

11.Zaharia OP., Strassburger K., Strom A., Bönhof GJ., Karusheva Y., Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019. 7:684–94.

12.Dennis JM., Shields BM., Henley WE., Jones AG., Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019. 7:442–51.

13.Tanabe H., Saito H., Kudo A., Machii N., Hirai H., Maimaituxun G, et al. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a Japanese retrospective cohort study. J Clin Med. 2020. 9:2083.

14.Slieker RC., Donnelly LA., Fitipaldi H., Bouland GA., Giordano GN., Åkerlund M, et al. Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia. 2021. 64:1982–9.

15.Hwang YC., Ahn HY., Jun JE., Jeong IK., Ahn KJ., Chung HY. Subtypes of type 2 diabetes and their association with outcomes in Korean adults - a cluster analysis of communi-ty-based prospective cohort. Metabolism. 2023. 141:155514.